Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide

Vulvovaginal atrophy is a chronic condition caused by estrogen deficiency which affects around 50% of postmenopausal women.  EMAS has published a clinical guide on the use of both topical estrogens and non-hormonal lubricants and moisturizers so that treatment can be individualized. Read more https://www.sciencedirect.com/science/article/pii/S037851222100061X

EMAS and IGCS Position statement on managing the menopause after gynecological cancer

February 11, 2020 – European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) Position statement on managing the menopause after gynecological cancer Worldwide, 1.3 million new gynecological cancer cases are diagnosed each year. Treatment can result in loss of ovarian function and, in women under the age of 45, early menopause.  This position…

Management of urinary incontinence in postmenopausal women: an EMAS clinical guide Maturitas 2021; 143: 223–230

30 September 2020 – A new clinical guide by the European Menopause and Andropause Society (EMAS) on the management of urinary incontinence in postmenopausal women is published in Maturitas. Urinary incontinence affects over 1 in 2 women aged over 60 years. The clinical guide provides evidence-based recommendations for the diagnosis and management of this common…

EMAS clinical guide on menopause symptom management in women with dyslipidemias

Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile. Published in Maturitas EMAS  has  produced an evidence-based clinical guide evaluating the effects on the lipid profile both of menopausal hormone therapy and of non-estrogen-based treatments for menopausal symptoms. Click here to read more. Menopause…